AR095660A1 - Métodos de fabricación para el control el contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes - Google Patents
Métodos de fabricación para el control el contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantesInfo
- Publication number
- AR095660A1 AR095660A1 ARP140100976A ARP140100976A AR095660A1 AR 095660 A1 AR095660 A1 AR 095660A1 AR P140100976 A ARP140100976 A AR P140100976A AR P140100976 A ARP140100976 A AR P140100976A AR 095660 A1 AR095660 A1 AR 095660A1
- Authority
- AR
- Argentina
- Prior art keywords
- content
- terminal
- synalic
- lisin
- galactose
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 229930182830 galactose Natural products 0.000 title 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 3
- 239000011701 zinc Substances 0.000 abstract 3
- 229910052725 zinc Inorganic materials 0.000 abstract 3
- 239000001963 growth medium Substances 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 229960000598 infliximab Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 abstract 1
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
Abstract
En la presente descripción se proporciona un método para producir un anticuerpo, como un anticuerpo inhibidor del Factor de Necrosis Tumoral a (anti-TNFa), por ejemplo, infliximab, que tiene un contenido de lisina C-terminal de aproximadamente 20% a aproximadamente 70%, y un contenido de ácido siálico de aproximadamente 1% a aproximadamente 20%, que comprende el cultivo de una célula que responde al zinc transfectada con ADN que codifica el anticuerpo en el medio de cultivo que comprende al menos 0,5 mM de zinc; y controlar la concentración de zinc en el medio de cultivo, y produce, de este modo, el anticuerpo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791094P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095660A1 true AR095660A1 (es) | 2015-11-04 |
Family
ID=51528780
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100976A AR095660A1 (es) | 2013-03-15 | 2014-03-13 | Métodos de fabricación para el control el contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes |
| ARP220100291A AR124871A2 (es) | 2013-03-15 | 2022-02-14 | Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100291A AR124871A2 (es) | 2013-03-15 | 2022-02-14 | Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20140273092A1 (es) |
| EP (1) | EP2970980B2 (es) |
| JP (1) | JP2016512029A (es) |
| KR (1) | KR102216003B1 (es) |
| CN (1) | CN105378086B (es) |
| AR (2) | AR095660A1 (es) |
| AU (2) | AU2014237635B2 (es) |
| BR (1) | BR112015022971B1 (es) |
| CA (1) | CA2907140A1 (es) |
| CY (1) | CY1120980T1 (es) |
| DK (1) | DK2970980T3 (es) |
| EA (1) | EA201591807A1 (es) |
| ES (1) | ES2690047T3 (es) |
| HR (1) | HRP20181741T1 (es) |
| IL (1) | IL240689B (es) |
| LT (1) | LT2970980T (es) |
| MX (1) | MX366910B (es) |
| PH (1) | PH12015501837B1 (es) |
| PL (1) | PL2970980T3 (es) |
| PT (1) | PT2970980T (es) |
| RS (1) | RS57791B1 (es) |
| SG (1) | SG11201507577RA (es) |
| SI (1) | SI2970980T1 (es) |
| SM (1) | SMT201800550T1 (es) |
| TW (1) | TWI630216B (es) |
| WO (1) | WO2014149935A1 (es) |
| ZA (1) | ZA201507671B (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| EP2830651A4 (en) | 2013-03-12 | 2015-09-02 | Abbvie Inc | HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| ES2690047T3 (es) * | 2013-03-15 | 2018-11-19 | Janssen Biotech, Inc. | Procedimientos de fabricación para controlar la lisina C-terminal, la galactosa y el contenido de ácido siálico en proteínas recombinantes |
| JP2016527911A (ja) | 2013-08-20 | 2016-09-15 | レック・ファーマシューティカルズ・ディー・ディーＬｅｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｄ．Ｄ． | ポリペプチドのα−アミド化および／またはＣ末端アミノ酸開裂を制御するための細胞培養用培地およびプロセス |
| WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| LT3370768T (lt) | 2015-11-03 | 2022-05-25 | Janssen Biotech, Inc. | Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas |
| CN108350416A (zh) * | 2015-11-09 | 2018-07-31 | 百时美施贵宝公司 | 操纵在cho细胞中产生的多肽的品质属性的方法 |
| JP2019502698A (ja) | 2015-12-17 | 2019-01-31 | ヤンセン バイオテツク，インコーポレーテツド | Ｈｌａ−ｄｒに特異的に結合する抗体及びその使用 |
| WO2017117218A1 (en) | 2015-12-30 | 2017-07-06 | Momenta Pharmaceuticals, Inc. | Methods related to biologics |
| US20180044430A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | FC Engineered Anti-TNFR Superfamily Member Antibodies Having Enhanced Atonistic Activity and Methods of Using Them |
| US10669344B2 (en) | 2016-08-12 | 2020-06-02 | Janssen Biotech, Inc. | Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US11149094B2 (en) | 2017-06-05 | 2021-10-19 | Janssen Biotech, Inc. | Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations |
| CR20190550A (es) | 2017-06-05 | 2020-04-05 | Janssen Biotech Inc | Anticuerpos que se unen específicamente a pd-1 y métodos de uso |
| WO2019077628A1 (en) * | 2017-10-16 | 2019-04-25 | Council Of Scientific & Industrial Research | ZINC SUPPLEMENTATION TO DECREASE GALACTOSYLATION OF RECOMBINANT GLYCOPROTEINS |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| JP2021524255A (ja) | 2018-05-24 | 2021-09-13 | ヤンセン バイオテツク，インコーポレーテツド | 単一特異性及び二重特異性抗体抗−ｔｍｅｆｆ２抗体並びにそれらの使用 |
| TWI874341B (zh) | 2018-12-18 | 2025-03-01 | 美商健生生物科技公司 | 產生異二聚體抗體之方法 |
| US20220081479A1 (en) | 2018-12-31 | 2022-03-17 | Momenta Pharmaceuticals, Inc. | Methods of producing ustekinumab |
| JP2022541332A (ja) | 2019-07-26 | 2022-09-22 | ヤンセン バイオテツク，インコーポレーテツド | カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用 |
| MX2022001799A (es) | 2019-08-15 | 2022-03-11 | Janssen Biotech Inc | Materiales y metodos para fragmentos variables de cadena unica mejorados. |
| PH12022552370A1 (en) | 2020-03-13 | 2023-12-18 | Janssen Biotech Inc | Materials and methods for binding siglec-3/cd33 |
| US12460001B2 (en) | 2020-05-27 | 2025-11-04 | Janssen Biotech, Inc. | Proteins comprising CD3 antigen binding domains and uses thereof |
| UY39345A (es) | 2020-07-29 | 2022-01-31 | Janssen Biotech Inc | Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos |
| US11926667B2 (en) | 2020-10-13 | 2024-03-12 | Janssen Biotech, Inc. | Bioengineered T cell mediated immunity, materials and other methods for modulating cluster of differentiation IV and/or VIII |
| US20240025992A1 (en) | 2020-10-22 | 2024-01-25 | Janssen Biotech, Inc. | Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses |
| KR20230137393A (ko) | 2021-01-28 | 2023-10-04 | 얀센 바이오테크 인코포레이티드 | Psma 결합 단백질 및 이의 용도 |
| CN117377694A (zh) | 2021-03-24 | 2024-01-09 | 詹森生物科技公司 | 包含cd3抗原结合结构域的蛋白质及其用途 |
| JP2024512035A (ja) | 2021-03-24 | 2024-03-18 | ヤンセン バイオテツク，インコーポレーテツド | Ｃｄ２２及びｃｄ７９ｂを標的とする抗体 |
| AU2022344595A1 (en) | 2021-09-13 | 2024-05-02 | Janssen Biotech, Inc | CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER |
| EP4405392A1 (en) | 2021-09-24 | 2024-07-31 | Janssen Biotech, Inc. | Proteins comprising cd20 binding domains, and uses thereof |
| CA3239224A1 (en) | 2021-11-22 | 2023-05-25 | Janssen Biotech, Inc. | Compositions comprising enhanced multispecific binding agents for an immune response |
| WO2024089551A1 (en) | 2022-10-25 | 2024-05-02 | Janssen Biotech, Inc. | Msln and cd3 binding agents and methods of use thereof |
| WO2025032510A1 (en) | 2023-08-07 | 2025-02-13 | Janssen Biotech, Inc. | Stabilized cd3 antigen binding agents and methods of use thereof |
| WO2025032508A1 (en) | 2023-08-07 | 2025-02-13 | Janssen Biotech, Inc. | Enpp3 and cd3 binding agents and methods of use thereof |
| WO2025137410A1 (en) * | 2023-12-20 | 2025-06-26 | Apogee Therapeutics, Inc. | Pharmaceutical compositions of anti-il-13 antibodies with and without c-terminal lysine |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4870163A (en) | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
| DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
| JP2647427B2 (ja) | 1987-04-24 | 1997-08-27 | 帝人株式会社 | 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット |
| AU640400B2 (en) | 1989-08-07 | 1993-08-26 | Peptide Technology Ltd. | Tumour necrosis factor binding ligands |
| US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
| US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| DE10199067I2 (de) | 1991-03-18 | 2006-03-16 | Univ New York | Fuer Menschlichen Tumornekrose-Faktor spezifische Monoklonale und Chimaere Antikoerper |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| CA2450289A1 (en) | 2003-03-20 | 2005-05-19 | Imclone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
| US20040185047A1 (en) | 2003-03-21 | 2004-09-23 | Jill Giles-Komar | Anti- TNF antibodies, compositions, methods and uses |
| SI1807504T1 (sl) | 2004-11-02 | 2011-05-31 | Ares Trading Sa | Brezserumski celiäśni kultivacijski medij za celice sesalcev |
| JP5628790B2 (ja) * | 2008-04-07 | 2014-11-19 | バイエル・ヘルスケア・エルエルシー | 糖タンパク質の組換え生産の方法 |
| MY169935A (en) * | 2011-04-29 | 2019-06-18 | Biocon Biologics India Ltd | "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof" |
| WO2013009648A2 (en) * | 2011-07-08 | 2013-01-17 | Momenta Pharmaceuticals, Inc. | Cell culture process |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| ES2690047T3 (es) * | 2013-03-15 | 2018-11-19 | Janssen Biotech, Inc. | Procedimientos de fabricación para controlar la lisina C-terminal, la galactosa y el contenido de ácido siálico en proteínas recombinantes |
-
2014
- 2014-03-07 ES ES14768761.0T patent/ES2690047T3/es active Active
- 2014-03-07 SM SM20180550T patent/SMT201800550T1/it unknown
- 2014-03-07 CN CN201480015815.5A patent/CN105378086B/zh not_active Expired - Fee Related
- 2014-03-07 EA EA201591807A patent/EA201591807A1/ru unknown
- 2014-03-07 PL PL14768761T patent/PL2970980T3/pl unknown
- 2014-03-07 WO PCT/US2014/021574 patent/WO2014149935A1/en not_active Ceased
- 2014-03-07 DK DK14768761.0T patent/DK2970980T3/en active
- 2014-03-07 MX MX2015012361A patent/MX366910B/es active IP Right Grant
- 2014-03-07 HR HRP20181741TT patent/HRP20181741T1/hr unknown
- 2014-03-07 BR BR112015022971-9A patent/BR112015022971B1/pt not_active IP Right Cessation
- 2014-03-07 JP JP2016500790A patent/JP2016512029A/ja active Pending
- 2014-03-07 LT LTEP14768761.0T patent/LT2970980T/lt unknown
- 2014-03-07 KR KR1020157029490A patent/KR102216003B1/ko not_active Expired - Fee Related
- 2014-03-07 PT PT14768761T patent/PT2970980T/pt unknown
- 2014-03-07 CA CA2907140A patent/CA2907140A1/en active Pending
- 2014-03-07 AU AU2014237635A patent/AU2014237635B2/en not_active Ceased
- 2014-03-07 RS RS20181228A patent/RS57791B1/sr unknown
- 2014-03-07 EP EP14768761.0A patent/EP2970980B2/en active Active
- 2014-03-07 SG SG11201507577RA patent/SG11201507577RA/en unknown
- 2014-03-07 SI SI201430848T patent/SI2970980T1/sl unknown
- 2014-03-13 AR ARP140100976A patent/AR095660A1/es not_active Application Discontinuation
- 2014-03-13 TW TW103108900A patent/TWI630216B/zh not_active IP Right Cessation
- 2014-03-13 US US14/207,915 patent/US20140273092A1/en not_active Abandoned
-
2015
- 2015-08-20 PH PH12015501837A patent/PH12015501837B1/en unknown
- 2015-08-20 IL IL240689A patent/IL240689B/en unknown
- 2015-10-14 ZA ZA2015/07671A patent/ZA201507671B/en unknown
- 2015-12-23 US US14/757,691 patent/US11149085B2/en not_active Expired - Fee Related
-
2018
- 2018-11-02 CY CY181101150T patent/CY1120980T1/el unknown
-
2020
- 2020-06-11 AU AU2020203864A patent/AU2020203864B2/en not_active Ceased
-
2021
- 2021-09-29 US US17/489,744 patent/US20220089712A1/en not_active Abandoned
-
2022
- 2022-02-14 AR ARP220100291A patent/AR124871A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124871A2 (es) | Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes | |
| HK1257341A1 (zh) | 硷性磷酸酯的制造 | |
| ZA201703241B (en) | Anti-c5 antibodies and methods of use | |
| MX376623B (es) | Cultivo celular metabolicamente optimizado. | |
| PH12018501282A1 (en) | Anti-c5 antibodies and methods of use | |
| SG10201901417UA (en) | Production of proteins in glutamine-free cell culture media | |
| AR095418A1 (es) | Métodos para aumentar el contenido de manosa en proteínas recombinantes | |
| MX2015014608A (es) | Novedosas moleculas de union biespecifica con actividad antitumoral. | |
| CL2011000792A1 (es) | Acido nucleico aislado que codifica mutante del factor de crecimiento de fibroblastos 21 (fgf21); vector; celula huesped; fgf21 mutante; proceso de produccion; composicion farmaceutica que lo comprende; y metodo para tratar un trastorno metabolico. | |
| MX2019003427A (es) | Composiciones para cultivo celular y metodos para la produccion de polipeptidos. | |
| AR089324A1 (es) | Composiciones, metodos y kits para la preparacion de proteinas recombinantes sialiladas | |
| MX2016007207A (es) | Metodos mejorados para la produccion de polipeptidos recombinantes. | |
| NZ705575A (en) | Recombinant clostridium botulinum neurotoxins | |
| EA202190736A1 (ru) | Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью | |
| MY180183A (en) | Methods and compositions for preventing norleucine misincorporation into proteins | |
| MX2020012649A (es) | Neoantígenos especificos de tumor y métodos de uso de estos. | |
| MX2016011465A (es) | Drimenol-sintasas y metodos para producir drimenol. | |
| MY182519A (en) | Method for producing lipid using acyl-acp thioesterase | |
| MX2013012986A (es) | Plantas que tienen uno o mas rasgos mejorados relacionados con el rendimento y un metodo para producirlas. | |
| MY182443A (en) | Method of producing lipid | |
| MX2015010887A (es) | Formulaciones y metodos para aumentar la produccion de proteinas recombinantes. | |
| MX2013013063A (es) | Plantas que tienen rasgos mejorados relacionados con el rendimiento y metodo para elaborar las mismas. | |
| WO2015003811A8 (en) | Methods for producing sialylated therapeutic proteins | |
| PH12015500459A1 (en) | Picornavirus-like particle production in plants | |
| AR094716A1 (es) | Utilización de una cepa procariótica de auxotrofía para aminoácidos revertida para la producción recombinante de un polipéptido |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |